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Abstract
Background:  Whether inhaled corticosteroids suppress airway inflammation in chronic
obstructive pulmonary disease (COPD) remains controversial. We sought to determine the effects
of inhaled corticosteroids on sputum indices of inflammation in stable COPD.
Methods:  We searched MEDLINE, EMBASE, CINAHL, and the Cochrane Databases for
randomized, controlled clinical trials that used induced sputum to evaluate the effect of inhaled
corticosteroids in stable COPD. For each chosen study, we calculated the mean differences in the
concentrations of sputum cells before and after treatment in both intervention and control groups.
These values were then converted into standardized mean differences to accommodate the
differences in patient selection, clinical treatment, and biochemical procedures that were employed
across original studies. If significant heterogeneity was present (p < 0.10), then a random effects
model was used to pool the original data. In the absence of significant heterogeneity, a fixed effects
model was used.
Results: We identified six original studies that met the inclusion criteria (N = 162 participants). In
studies with higher cumulative dose (≥ 60 mg) or longer duration of therapy (≥ 6 weeks), inhaled
corticosteroids were uniformly effective in reducing the total cell, neutrophil, and lymphocyte
counts. In contrast, studies with lower cumulative dose (< 60 mg) or shorter duration of therapy
(< 6 weeks) did not demonstrate a favorable effect of inhaled corticosteroids on these sputum
indices.
Conclusions: Our study suggests that prolonged therapy with inhaled corticosteroids is effective
in reducing airway inflammation in stable COPD.
Background
Chronic obstructive pulmonary disease (COPD) is charac-
terized by prominent airway inflammation [1,2]. The
intensity of the inflammation strongly correlates with dis-
ease severity [3,4] and increases even further during exac-
erbations [5]. Moreover, increased expression of
inflammatory markers in the sputum is associated with
increased risk of exacerbations [6]. The attenuation of the
inflammatory process, on the other hand, is associated
with improvements in lung function and airway
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hyperresponsiveness in COPD [7]. It is possible therefore
that the inflammatory process is an integral component in
COPD pathogenesis and may represent an important
therapeutic target in improving the health status and out-
comes of COPD patients [1,2].
One potential therapy for down-regulating the inflamma-
tory process in the airways is through the use of corticos-
teroids, which are potent but non-specific anti-
inflammatory agents. Some in vitro studies have demon-
strated that inhaled corticosteroids can modulate certain
aspects of the inflammatory cascade in COPD [8,9]; how-
ever, other studies have shown less favorable results
[10,11]. Despite this uncertainty, large clinical trials have
shown that these medications reduce clinically relevant
exacerbations by ~30% and improve health status of
patients with moderate to severe disease [12]; their with-
drawal, on the other hand, leads to increased risk of exac-
erbations and worsening of health status [13]. Since
airway inflammation is associated with exacerbations [6]
and since inhaled corticosteroids reduce exacerbations
[12], they may also have salutary effect on airway inflam-
mation in COPD. However, to date, the clinical studies,
which have addressed this issue, have been small in size
and scope and may not have had sufficient statistical
power (on their own) to detect subtle but important effect
of these medications on inflammatory indices in the air-
ways. Additionally, there may be important methodologic
differences between the positive and negative studies that
could potentially explain the discrepancy. We, therefore,
conducted a systematic review and a meta-analysis to
determine whether inhaled corticosteroids do or do not
suppress airway inflammation in patients with stable
COPD and to explore the potential causes for the hetero-
geneity in reports.
Methods
Search for relevant studies
MEDLINE (1966–2004), EMBASE (1980–2004),
CINAHL (1982–2004), and the Cochrane Databases were
searched for randomized, controlled clinical trials that
used induced sputum to evaluate the effect of inhaled ster-
oids on airway inflammation in stable COPD. The search
was restricted on articles published in the English lan-
guage, using human participants. Subject headings
included disease-specific search terms (COPD, lung dis-
eases, pulmonary diseases, airway obstruction, obstruc-
tive pulmonary disease, chronic obstructive pulmonary
disease, bronchitis, emphysema, pulmonary emphysema,
or mediastinal emphysema), drug-specific search terms
(glucocorticosteroids, corticosteroids, beclomethasone,
budesonide, fluticasone, or triamcinolone), and labora-
tory method-specific search terms (biopsy, bronchoalveo-
lar lavage, or sputum). We also scanned the
bibliographies and reference lists of retrieved articles to
supplement the electronic searches. We contacted the pri-
mary authors for additional data and/or clarification of
data.
Study selection and data abstraction
The primary objective of this meta-analysis was to com-
pare the changes in sputum inflammatory indices among
stable COPD patients before and after treatment with
inhaled corticosteroids, using the control group in each
individual studies as the referent. We chose sputum as the
primary source of the analysis because there was a marked
scarcity of quality studies which had evaluated the effect
of inhaled corticosteroids from bronchoalveolar lavage
fluid or tissue biopsy specimens. The inflammatory indi-
ces included total cell, neutrophil, macrophage, eosi-
nophil, lymphocyte, and epithelial cell counts and
interleukin (IL)-8 levels. Since the actions of oral corticos-
teroids may differ from those of inhaled corticosteroids,
we excluded studies that evaluated the effects of oral cor-
ticosteroids on sputum inflammatory indices. From each
selected article, two investigators (WQG, DDS) abstracted
the following baseline information: the source of data,
study design, inclusion and exclusion criteria, concomi-
tant drugs, demographics of study participants including
sample size, age, sex, current smoking status, pack-years of
smoking history, predicted forced expiratory volume in
one second (FEV1), the ratio of FEV1 to forced vital capac-
ity (FVC), percent predicted reversibility with inhaled
bronchodilator, the specific brand of inhaled corticoster-
oids and the dose as well as the duration of therapy.
Cumulative dose of inhaled corticosteroids was calculated
by multiplying the average daily dose by the total days of
treatment. All formulations were converted to beclometh-
asone equivalent based on the recommendations from
the Canadian Asthma Consensus Report [14]. Any ques-
tions or discrepancies were resolved through iteration and
consensus.
Statistical methods
To accommodate any differences in patient selection, clin-
ical treatment, and biochemical procedures that were
employed across the original studies, we converted the
absolute mean differences in the concentrations of the
inflammatory cells between the intervention and control
groups into standardized mean differences. For each
study, standardized mean difference was derived by divid-
ing the mean change in the inflammatory cell concentra-
tion at follow-up visit from the baseline visit between
intervention and control groups by a pooled standard
deviation of the mean change [15,16]. A negative stand-
ardized mean difference indicated that the participants
assigned to inhaled corticosteroids had lower cell counts
compared with placebo at the end of the study phase;
whereas a positive number denoted increased cell count
relative to the control group. For each inflammatory cell,BMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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we tested the heterogeneity of results across the studies,
using a Cochran Q test. If significant heterogeneity was
present (p < 0.10), then a random effects model was used.
In the absence of significant heterogeneity, a fixed effects
model was used [16]. We also evaluated the potential
modifying effect of cumulative dose and the duration of
therapy of the trials. We reasoned that trials that had
higher cumulative dose (or longer duration of therapy)
defined as greater or equal to the median cumulative dose
(or duration of therapy) of all the trials included in this
meta-analysis would be more "positive" than those that
used lower doses (or were shorter in duration). All analy-
ses were conducted using Review Manager version 4.2
(Revman; The Cochrane Collaboration, Oxford, England)
and were two-tailed in nature.
Results
A summary of the search strategy is shown in Figure 1. The
original search yielded 155 and 63 citations in MEDLINE
and EMBASE, respectively. CINAHL and the Cochrane
Databases did not contribute to the search results. The
abstracts of these articles were selected and reviewed. Of
these, 21 articles were retrieved for a detailed review. We
excluded the study from Loppow and colleagues [17]
because it included 6 patients with a positive skin prick
test against at least one common airborne allergen and 4
patients who had FEV1/FVC > 0.7. We excluded additional
14 articles because of other reasons (Figure 1). This proc-
ess left 6 original studies meeting the inclusion and exclu-
sion criteria, which were used for the analyses [7,18-22].
The baseline information concerning the study designs is
summarized in Table 1. The relevant demographic data
Study selection process Figure 1
Study selection process
 
Search results: n=218 
  MEDLINE: n=155 
  EMBASE:  n=63 
Did not meet criteria 
or duplicate articles:
 n=198   
Studies retrieved: 
n=21 
Did not meet definition of COPD: n=1
Oral medication: n=4 
No sputum indices reported: n=10 
Studies included in analyses: n=6BMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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are summarized in Table 2. All 162 patients were current
or ex-smokers with post-bronchodilator FEV1 <70 % pre-
dicted, FEV1 to FVC ratio <0.7, and reversibility with bron-
chodilator of <15%. The medications used included
budesonide, beclomethasone dipropionate, and flutica-
sone propionate. The study period of these trials ranged
from 2 to 12 weeks.
After treatment with inhaled corticosteroids, the total cell
counts decreased. Overall, the standardized mean differ-
ence between steroid and control groups was -0.43 units
Table 1: Baseline information on original studies included in the meta-analysis.
Source Setting Design Inclusion Criteria Exclusion Criteria Concomitant 
drugs
Withdrawal Sputum 
specimen
Sugiura et al 
2003 [7]
NR Randomized, placebo-
controlled parallel 
design.
FEV1/FVC < 0.7; all 
patients wereex-
smokers who had 
stopped smoking for 
at least 1 year 
beforethe study.
A history of perennial allergic 
rhinitis; positiveallergen skin prick 
tests and RAST assay; a history of 
periodicwheezing; an improvement 
in FEV1 of more than 12 % predicted 
oran absolute increase of 200 ml 
after inhalation of 200 µg salbutamol; 
had bronchial or respiratory tract 
infectionsin the month preceding the 
study; had taken systemic steroids in 
the 2 monthsbefore the study or 
inhaled steroids in the month 
beforethe study.
NR None NR
Keatings et 
al 1997 [18]
Outpatient 
clinics in 
different 
hospitals
Randomized, single-
blind, crossover design 
with 3–7 day run in 
period. The clinical part 
of the study was single-
blind, but all differential 
cell counting and 
assayswere carried out 
in a double blind fashion.
FEV1/FVC < 0.7; FEV1 
< 70% predicted; 
reversibility with 
inhaled albuterol of 
<10% of predicted 
FEV1; smoking history 
of at least 10 pack-
years; negative results 
on skin prick testing 
to four common 
aeroallergens.
Patients who had taken inhaled or 
oral steroids or who had suffered an 
exacerbation of their airway disease 
in the previous 6 weeks, or patients 
with any history of asthma or 
variability in symptoms were 
excluded.
Albuterol was 
allowed.
2 subjects NR
Culpitt et al 
1999 [19]
Outpatient 
clinic
Randomized, double-
blind, placebo-
controlled crossover 
design with a run-in 
period of 2 weeks.
FEV1/FVC < 0.7; 
postbronchodilat or 
FEV1 <85% predicted; 
reversibility with 
inhaled β2-agonist of 
<15% of predicted 
FEV1; smoking history 
of at least 20 pack-
years.
Patients who had taken inhaled or 
oral steroids or who had suffered an 
exacerbation of their airway disease 
in the previous 6 weeks, or patients 
with any history of asthma or atopy 
or variability in symptoms were 
excluded.
Three subjects had 
concomitant 
treatment with 
albuterol (200 µg 
twice a day) and 
ipratropium 
bromide (40 µg 
twice a day), one 
subject with 
albuterol (200 µg as 
needed) alone.
12 subjects Samples were 
considered 
adequate for 
analysis if there was 
< 50% squamous 
cell contamination.
Confalonieri 
1998 [20]
Outpatient 
clinic
Randomised, controlled, 
open study. The clinical 
parts of the study was 
open, but all differential 
cell counting was 
carried out in a double 
blind fashion.
FEV1/FVC <88% of 
predicted in men and 
<89% in women; all 
patients were current 
smokers.
Patients who had taken inhaled or 
oral steroids or had suffered a 
respiratory tract infection in the 
previous three months were 
excluded.
None of the 
patients was taking 
theophyllines or 
long acting β2 
agonists.
None Samples were 
discarded if viability 
levels were 50% or 
less, or squamous 
contamination was 
20% or more. An 
overall differential 
cell count on 500 
nucleated non-
squamous cells was 
performed by two 
examiners and 
results reported as 
mean of the two 
counts.
Mirici et al 
2001 [21]
Outpatient 
clinic
Randomized, double-
blind, placebo-
controlled parallel 
design.
FEV1 < 70% predicted; 
no self-reported 
asthma; reversibility 
with inhaled 
terbutaline of <15% of 
predicted FEV1; 
current smokers.
Long-term treatment with oral or 
inhaled steroids within 6 months of 
study entry; A respiratory tract 
infection in previous 3 months; 
pregnancy or lactation, or presence 
of other serious systemic diseases.
β2 – agonists of all 
kinds, theophylline, 
and mucolytics were 
allowed.
10 subjects Samples were 
discarded if 
viabilitylevels were 
50% or less, or 
squamous 
contamination was 
20% or more
Yildiz et al 
2000 [22]
Outpatient 
clinic
Randomized, placebo-
controlled parallel 
design with a run-in 
period of 2 weeks.
FEV1/FVC < 0.7; FEV1 
< 70% predicted; 
reversibility with 
inhaled albuterol of 
<10% of predicted; 
smoking history of at 
least 10 pack-years.
Patients with any history of asthma 
or variability in symptoms, and 
patients who had taken inhaled or 
oral steroids or had suffered a 
respiratory tract infection or 
exacerbation in the previous 6 
weeks were excluded.
All of the patients 
continued to inhale 
both salbutamol and 
ipatropium bromide. 
In 9 patients, 
sustained release 
theophylline was 
also administered.
None NR
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; NR, not reported.BMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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Table 2: The characteristics of COPD patients at baseline.
Source Number 
of 
Patients
Age 
(year)
Men 
(%)
Current 
Smokers 
(%)
Pack-
years
FEV1
(% predicted)
Ratio (%) Reversibility 
(% predicted)
Drug Dose
(mg/day)
Duration 
(weeks)
Cumulative 
dose (mg) #
Sugiura [7] 18‡ 70(7) 89 0* NR 1.2(0.4)† <70 <12 Beclomethasone 0.8 4 22.4
Keatings [18] 26 45–78 60 46 >10 35.1(4.7) <70 <10 Budesonide 1.6 2 28.0
Culpitt [19] 26 43–73 62 69 >20 49.5(16.6) <70 <15 Fluticasone 1.0 4 56.0
Confalonieri 
[20]
34 58 (5) 59 100 NR 59.7(37.1) 67 (5) NR Beclomethasone 1.5 8 84.0
Mirici [21] 40 53(10) 75 100 26.5 (16.1) 62.0(7.4) NR <15 Budesonide 0.8 12 84.0
Yildiz [22] 18 64(7) 78 89 52.0 (23.4) 44.5(2.7) 57 (3) <10 Fluticasone 1.5 8 168.0
† FEV1, liter;
‡ 6 patients in control group
* All subjects were ex-smokers and stopped smoking for at least 1 year.
# Cumulative dose = daily dose × days × adjusted factor for beclomethasone equivalence [14].
Continuous variables are presented as mean (SD)
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ratio, the ratio of FEV1 to FVC; NR, not reported/not 
calculable.
Effect of inhaled corticosteroids on total cell counts in the sputum of stable COPD patients Figure 2
Effect of inhaled corticosteroids on total cell counts in the sputum of stable COPD patients
-2.0 -1.6 -1.2 -0.8 -0.4 0.0 0.4 0.8 1.2 1.6 2.0
Confalonieri20
Keatings18
Mirici21
Sugiura7
Yildiz22
Overall Pooled Summary
Pooled result (cumulative dose < 60 mg & < 6 weeks)
Pooled result (cumulative dose ≥ 60 mg & ≥ 6 weeks)
Culpitt19
Standardized Mean Difference (95% CI) of Total Cell Count
56
84
Study
Cumulative Dose
(mg)
28
22
84
168
Favors 
Steroids
Favors 
Controls
Duration
(weeks)
4
2
4
8
12
8BMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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(95% confidence interval, CI, -0.75 to -0.11), indicating
that inhaled corticosteroids had a favorable effect in
reducing total count compared with controls (test for het-
erogeneity, p = 0.35) (Figure 2). Importantly, the total
cumulative dose of inhaled corticosteroids calculated on
the basis of mean daily dose and duration of therapy
made a material difference to the results. In the studies in
which patients were exposed to 60 mg or greater of
beclomethasone or its equivalent for the duration of the
trial, inhaled corticosteroids were effective in reducing the
total sputum cell count (-0.68 units; 95% CI, -1.11 to -
0.26). In contrast, trials with cumulative dose of < 60 mg
did not demonstrate a favorable effect of inhaled corticos-
teroids on this sputum index (-0.11 units; 95% CI, -0.58
to 0.37). All of the trials with the higher cumulative dose
had exposed the trial participants to inhaled corticoster-
oids for at least 6 weeks; whereas, the trials with the lower
cumulative dose was uniformly less than 6 weeks in
duration.
Inhaled corticosteroids had a salutary effect on neutrophil
counts in the sputum. As compared with the control
group, the standardized mean difference in those treated
with inhaled corticosteroids was -2.16 units (95% CI, -
3.81 to -0.50; test for heterogeneity, p < 0.001) (Figure 3).
Similar to the findings on the total cell count, trials with a
cumulative dose of ≥ 60 mg of beclomethasone (or at least
6 weeks of therapy) demonstrated a significant effect of
these medications on sputum neutrophil count (-4.27
units; 95% CI, -6.87 to -1.66); whereas, trials with cumu-
lative dose of < 60 mg (or less than 6 weeks of therapy)
Effect of inhaled corticosteroids on neutrophils in the sputum of stable COPD patients Figure 3
Effect of inhaled corticosteroids on neutrophils in the sputum of stable COPD patients
-10.0-8.0 -6.0 -4.0 -2.0 0.0 2.0 4.0 6.0 8.0 10.0 -10.0-8.0 -6.0 -4.0 -2.0 0.0 2.0 4.0 6.0 8.0 10.0 -10.0-8.0 -6.0 -4.0 -2.0 0.0 2.0 4.0 6.0 8.0 10.0
Keatings18
Sugiura7
Pooled result (cumulative dose < 60 mg & < 6 weeks)
Culpitt19 56
Study
Cumulative Dose
(mg)
28
22
Duration
(weeks)
4
2
4
Confalonieri20
Mirici21
Yildiz22
84
84
168
8
12
8
Overall Pooled Summary
Pooled result (cumulative dose ≥ 60 mg & ≥ 6 weeks)
Standardized Mean Difference (95% CI) of Neutrophils
Favors 
Steroids
Favors 
ControlsBMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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failed to demonstrate a beneficial effect (-0.26 units; 95%
CI, -0.74 to 0.22).
Inhaled corticosteroids also reduced the lymphocyte
counts in the sputum (standardized mean difference, -
0.39 units, 95% CI, -0.74 to -0.05; test for heterogeneity,
p = 0.58) (Figure 4). Trials with cumulative dose of ≥ 60
mg (or at least 6 weeks of therapy) demonstrated a signif-
icant effect (standardized mean difference, -0.59 units;
95% CI, -1.01 to -0.17); whereas, trials with cumulative
dose < 60 mg (or less than 6 weeks of therapy) failed to
demonstrate a salutary effect on this endpoint (standard-
ized mean difference, 0.02; 95% CI, -0.59 to 0.62).
These medications were also effective in reducing epithe-
lial cell counts compared with the controls (standardized
mean difference, -0.51 units, 95% CI, -0.98 to -0.05; test
for heterogeneity, p = 0.20) (Figure 5). There was an insig-
nificant trend towards reducing eosinophil counts in the
sputum with inhaled corticosteroid therapy (standardized
mean difference, -0.28 units, 95% CI, -0.62 to 0.07; test
for heterogeneity, p = 0.22) (Figure 6). Inhaled corticos-
teroids did not appear to have any significant effect on
macrophage concentrations in the sputum (standardized
mean difference, -0.02 units, 95% CI, -0.34 to 0.29; test
for heterogeneity, p = 0.65) (Figure 7). Inhaled corticos-
teroids did not have significant effect on sputum IL-8 lev-
els (standardized mean difference, -0.22 units; 95% CI, -
0.77 to 0.32; test for heterogeneity, p = 0.84).
To evaluate whether the magnitude of the reduction in the
inflammatory cells was modified by the absolute levels of
Effect of inhaled corticosteroids on lymphocytes in the sputum of stable COPD patients Figure 4
Effect of inhaled corticosteroids on lymphocytes in the sputum of stable COPD patients
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0
Standardized Mean Difference (95% CI) of Lymphocytes
Study
Sugiura7
Keatings18
Cumulative Dose
(mg)
28
22
Duration
(weeks)
4
2
Pooled result (cumulative dose < 60 mg & < 6 weeks)
Confalonieri20
Mirici21
Yildiz22
Overall Pooled Summary
Pooled result (cumulative dose ≥ 60 mg & ≥ 6 weeks)
84
84
168
8
12
8
Favors 
Steroids
Favors 
ControlsBMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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the inflammatory cells in the sputum at baseline, we per-
formed a stratified analysis based on the total cell counts
at baseline (see Table 3). No significant patterns were
observed with any of the cell lines suggesting that baseline
"cell load" in the sputum was not a predictor of response
to inhaled corticosteroids.
After treatment with inhaled steroids, lung function
improved slightly but neither the improvement in FEV1
nor FVC reached statistical significance. For predicted
FEV1, the overall standardized mean difference was 0.26
units, 95% CI, -0.06 to 0.57 (test for heterogeneity, p =
0.62) (Figure 8). For predicted FVC, the overall standard-
ized mean difference was 0.31 units; 95% CI, -0.09 to 0.70
(test for heterogeneity, p = 0.23).
Discussion
By combining data across the clinical studies, we
increased statistical power to demonstrate a salutary effect
of moderate to high doses of inhaled corticosteroids on
some inflammatory indices in the sputum of patients with
stable COPD. Over a short term, these medications
reduced neutrophil, lymphocyte and epithelial cell counts
in the sputum of stable COPD patients. They had smaller
(and insignificant) effect on sputum eosinophils and IL-8.
They had little effect on sputum macrophages. Although
the magnitudes of these reductions were relatively small,
they may explain why inhaled corticosteroids decrease
cough and sputum production [23], reduce exacerbations
[24], and hospitalizations [25].
Effect of inhaled corticosteroids on epithelial cells in the sputum of stable COPD patients Figure 5
Effect of inhaled corticosteroids on epithelial cells in the sputum of stable COPD patients
-1.5 -1.0 -0.5 0.0 0.5 1.0 1.5
Standardized Mean Difference (95% CI) of Epithelial Cells
Study
Cumulative Dose
(mg)
Duration
(weeks)
Favors 
Steroids
Favors 
Controls
Confalonieri20 84 8
Mirici21 84 12
Overall Pooled SummaryBMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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We also found that duration of therapy and total cumula-
tive dose, which are related constructs, made a material
difference to the overall results. Short trials (less than 6
weeks in duration) were uniformly "negative"; while
longer term trials (at least 6 weeks of therapy) were mostly
positive. Similarly, trials that exposed the patients to
higher cumulative dose were more "positive" than those
that exposed patients to lower dose. This suggests that
duration of therapy and total cumulative doses may be
important determinants of the effect of inhaled corticos-
teroids on airway inflammation.
Although corticosteroids delay neutrophil apoptosis and
may increase neutrophil survival [11,26], they also have
significant inhibitory action on neutrophil performance.
Likely through the annexin-I (lipocortin-1) pathways, for
instance, corticosteroids interfere with neutrophil chemo-
taxis, adhesion, transmigration, oxidative bursts, and
phagocytosis, thereby down-regulating the overall inflam-
matory cascade [9,27]. Indeed, Llewellyn-Jones and co-
workers [28] showed that 4 weeks of inhaled fluticasone
therapy can significantly reduce sputum chemotactic
activity for neutrophils and increase its elastase inhibitory
capacity in patients with well-characterized COPD. These
data suggest that inhaled corticosteroids can reduce
recruitment and/or adhesion of neutrophils to the airways
of COPD patients, thereby lowering the overall concentra-
tion of these cells in COPD airways.
Superficially, the present data on sputum eosinophils
appear to be inconsistent with the known effect of corti-
costeroids in general on eosinophils. Many experiments
Effect of inhaled corticosteroids on eosinophils in the sputum of stable COPD patients Figure 6
Effect of inhaled corticosteroids on eosinophils in the sputum of stable COPD patients
Standardized Mean Difference (95% CI) of Eosinophils
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have shown that eosinophils are exquisitely sensitive to
corticosteroids [29,30]. The current data, however, suggest
otherwise. Several studies have demonstrated that among
COPD patients with irreversible airflow obstruction (as
was the case for a majority of patients enrolled in the orig-
inal studies contained in this meta-analysis), eosinophils
are present in relatively small quantities in the sputum of
such patients [10,31]. In most COPD patients, eosi-
nophils account for less than 2% of the total cells in the
sputum. This could have introduced a "floor" bias
wherein the overall signal to the noise ratio for eosi-
nophils may have been too small to detect subtle but
important effect of inhaled corticosteroids on these cells.
Although by combining data from these published studies
we increased the power of the present analysis to detect
salient changes in the inflammatory indices of the
sputum, we may still have had insufficient power for anal-
yses of cells with a relatively small signal. Our analysis
may also have had insufficient power to assess the effects
of inhaled corticosteroids on FEV1. Although there was a
trend towards improvement, we did not find a statistically
significant effect of inhaled corticosteroids on FEV1.
Larger randomized trials have demonstrated, however,
that inhaled corticosteroids significantly improve FEV1
over the first three to six months of therapy [25,32-34],
suggesting that for certain endpoints our present analysis
still lacked sufficient power. Therefore, the "negative"
associations must be interpreted cautiously. It is also
important to note that none of the studies included in the
present review evaluated the effects of inhaled corticoster-
oids on the function or performance of inflammatory cells
in the airway. Thus, we can not discount the possibility
Effect of inhaled corticosteroids on macrophages in the sputum of stable COPD patients Figure 7
Effect of inhaled corticosteroids on macrophages in the sputum of stable COPD patients
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that these medications could have salutary effects on the
functional performance of these cells.
In the present review, we did not include randomized
studies that used bronchoalveolar lavage (BAL) or bron-
chial biopsies to measure inflammatory cells in the air-
ways. However, in one study, Balbi and colleagues [35]
observed significant reductions in the total number of
cells, neutrophil counts, IL-8, and myeloperoxidase levels
in the BAL fluid of COPD patients after 6 weeks of inhaled
beclomethasone therapy. A similar finding was observed
and reported by Thompson and coworkers [36]. In
another experiment, Hattotuwa at al [23] randomly
treated a group of COPD patients with 3 months of
inhaled fluticasone propionate (1 mg/d) or placebo. The
group that received fluticasone had significantly fewer
mast cells in the subepithelial layer as well as a reduced
ratio of CD8 to CD4 positive cells in the epithelial layer
than those treated with placebo. Most importantly, the
fluticasone group had significant improvements in cough
and sputum scores and decreased use of reliever medica-
tions and experienced fewer exacerbations than did the
placebo group [23]. Verhoeven et al [37] evaluated 23
patients with COPD and randomly treated 10 patients to
fluticasone (1 mg/d) and the remainder to placebo. After
6 months, fluticasone treatment resulted in a significant
reduction in the number of MBP and CD68 positive cells
in the lamina propria and reduced tryptase levels in the
epithelium. In addition, there was a trend towards fewer
CD3, CD4 CD68 positive cells in epithelium of the group
Effect of inhaled corticosteroids on FEV11% predicted in stable COPD patients. Abbreviation: FEV1, forced expiratory volume  in one second Figure 8
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treated with fluticasone compared with the group treated
with placebo [37]. The results from the BAL and bronchial
biopsy studies largely support data from the sputum stud-
ies and are consistent with the notion that inhaled corti-
costeroids reduce airway inflammation in COPD.
We also did not include studies that used systemic corti-
costeroids. Barcyk and colleagues [38] have reported that
oral prednisone therapy (0.5 mg/kg/d) for 2 weeks signif-
icantly reduced myeloperoxidase levels in the sputum of
COPD patients. Brightling and colleagues [39] showed
that 2 weeks of oral prednisone therapy resulted in fewer
eosinophils in the sputum of COPD patients. Similar
findings were reported by Fujimoto and colleagues [40].
These data suggest that oral prednisone can reduce certain
components of airway inflammation (e.g. eosinophils) in
COPD; however, most of the studies were very short in
duration, which makes it difficult to compare these data
against those studies that used inhaled corticosteroids.
Although in the present review, we could not adequately
determine the effects of tobacco smoke exposure on the
relationship between inhaled corticosteroids and airway
inflammation, there is a growing body of evidence to sug-
gest that active smoking may attenuate the effectiveness of
corticosteroids in suppressing airway inflammation.
Active smoking increases oxidative stress and up-regulates
the production of various pro-inflammatory cytokines
including Il-6, IL-8, IL-1β and monocyte chemoattractant
protein-1 in airways, which may through a series of com-
plex pathways lead to a state of steroid resistance [41].
Additionally, cigarette smoke may reduce histone deacety-
lase activity and its expression in alveolar macrophages,
making these cells relatively resistant to corticosteroids
since one of the principal targets of corticosteroid action
is by switching off gene expression of inflammatory genes
through the recruitment of histone deacetylases [41].
Therefore smoking cessation remains the single most
important intervention in COPD management. Inhaled
corticosteroids should be considered as a possible adjunc-
tive therapy in patients who remain symptomatic despite
smoking cessation.
There are certain limitations with the present analysis.
First, although we used stringent entry criteria in order to
minimize the heterogeneity in the research methods
employed by each of the selected study, there were still
some variations in the study design, the exposure medica-
tions, and the target population across the original stud-
ies. However, the differences in the characteristics of the
studies were relatively small and unlikely to have materi-
ally affected the overall findings of the current review. We
also contacted the primary authors to clarify any ambigu-
ities or to obtain additional data, where necessary, to
further minimize the "noise" inherent to meta-analyses.
Moreover, to accommodate various differences in the
methodology of data collection and laboratory tech-
niques employed across the original studies, we converted
the individual data into standardized mean estimates,
which enhanced the comparability of data across the orig-
inal studies. Second, it is possible that corticosteroid ther-
apy could have affected the volume of sputum recovery,
decreasing the total sputum cell counts in those patients
exposed to this therapy. To mitigate this possibility, the
cell counts were expressed as cells per volume of sputum
recovered.
Conclusions
In summary, the present meta-analysis suggests that
inhaled corticosteroids when used for longer than 6 weeks
can significantly reduce neutrophil counts and other
inflammatory indices in the sputum of patients with
stable COPD. Large randomized controlled trials are
needed in the future to confirm these early findings and to
determine whether these salutary effects persist longer
than 3 to 4 months of therapy.
Table 3: Total and differential cell counts at baseline and the standard mean difference (SMD) in cell counts between intervention 
group and placebo group after treatment.
Source Total cells Neutrophils Lymphocytes Eosinophils Macrophages
Number 
(× 104/mL)
SMD (95% CI) Number 
(× 104/mL)
SMD (95% CI) Number 
(× 104/mL)
SMD (95% CI) Number 
(× 104/mL)
SMD (95% CI) Number 
(× 104/mL)
SMD (95% CI)
Yildiz [22] 350.0 -0.6 (-1.6 to 0.4) 260.0 -2.2 (-3.4 to -1.0) 3.5 -0.5 (-1.4 to 0.5) 7.0 -1.1 (-2.1 to -0.1) 80.0 0.2 (-0.5 to 0.9)
Confalonieri 
[20]
219.0 -0.4 (-1.1 to 0.3) 158.8 -3.4 (-4.5 to -2.3) 6.6 -0.5 (-1.2 to 0.2) 6.2 -0.6 (-1.3 to 0.1) 45.0 -0.3 (-0.9 to 0.3)
Mirici [21] 196.5 -1.0 (-1.7 to -0.3) 146.5 -7.5 (-9.3 to -5.6) 1.6 -0.7 (-1.4 to -0.1) 1.6 0.2 (-0.4 to 0.8) 38.2 0.5 (-0.5 to 1.5)
Sugiura [7] 165.7 0.2 (-0.8 to 1.2) 102.9 0.1 (-0.9 to 1.1) 6.1 0.04 (-0.9 to 1.0) 4.5 -0.2 (-1.2 to 0.8) 52.0 -0.3 (-1.1 to 0.5)
Culpitt [19] 165.0 -0.3 (-1.1 to 0.5) 145.0 -0.4 (-1.2 to 0.4) NR NR NR NR 25.0 -0.2 (-0.9 to 0.6)
Keatings [18] 6.3* -0.1 (-0.9 to 0.7) 4.3* -0.4 (-1.1 to 0.4) 6.0* 0.0 (-0.7 to 0.8) 0.2* -0.2 (-1.0 to 0.6) 1.8* 0.2 (-0.7 to 1.2)
Pooled 
Summary
-0.4 (-0.8 to -0.1) -2.2 (-3.8 to -0.5) -0.4 (-0.7 to -0.1) -0.3 (-0.6 to 0.1) -0.02 (-0.3 to 0.3)
* cell count/ml
Abbreviations: NR, not reported/not calculable.BMC Pulmonary Medicine 2005, 5:3 http://www.biomedcentral.com/1471-2466/5/3
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Abbreviations
COPD chronic obstructive pulmonary disease
FEV1 forced expiratory volume in 1 second
FVC forced vital capacity
SD standard deviationIL-8 interleukin-8
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